|
| |
BioPortfolio's Approved Drugs DatabaseTasignaNilotinib Hydrochloride MonohydrateDownload PDF containing detailed information.
Press Releases About Tasigna:
|
 |
| Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report |
24th September, 2009 |
Reportlinker |
-- SERMS
The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type
|
| Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia |
8th December, 2008 |
Novartis |
TASIGNA prolongs the QT interval. Sudden deaths have been reported in
patients receiving nilotinib. TASIGNA should not be used in patients with
hypokalemia, hypomagnesemia, or long QT
|
| Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation |
9th September, 2008 |
Caliper Life Sciences, Inc. |
HOPKINTON, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences,
Inc. (Nasdaq: CALP), a leading provider of tools and services for drug
discovery and life sciences research, today
|
This page has been viewed 19 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Tasigna across BioPortfolio, or for Tasigna Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|